AU713877B3 - Novel compound - Google Patents

Novel compound Download PDF

Info

Publication number
AU713877B3
AU713877B3 AU23938/99A AU2393899A AU713877B3 AU 713877 B3 AU713877 B3 AU 713877B3 AU 23938/99 A AU23938/99 A AU 23938/99A AU 2393899 A AU2393899 A AU 2393899A AU 713877 B3 AU713877 B3 AU 713877B3
Authority
AU
Australia
Prior art keywords
paroxetine
solution
paroxetine methanesulfonate
methanesulfonate
crystalline
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU23938/99A
Other languages
English (en)
Inventor
Andrew Simon Dr Craig
Victor Witold Jacewicz
Alan David Dr Jones
Deirdre Dr O'Keeffe
Michael Urquhart
Neal Mr Ward
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Ltd
Original Assignee
SmithKline Beecham Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27269380&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU713877(B3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9814316.7A external-priority patent/GB9814316D0/en
Priority claimed from GBGB9821732.6A external-priority patent/GB9821732D0/en
Priority claimed from GBGB9902935.7A external-priority patent/GB9902935D0/en
Application filed by SmithKline Beecham Ltd filed Critical SmithKline Beecham Ltd
Application granted granted Critical
Publication of AU713877B3 publication Critical patent/AU713877B3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Inorganic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AU23938/99A 1998-07-02 1999-04-23 Novel compound Ceased AU713877B3 (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GB9814316 1998-07-02
GBGB9814316.7A GB9814316D0 (en) 1998-07-02 1998-07-02 Novel compounds
GBGB9821732.6A GB9821732D0 (en) 1998-10-06 1998-10-06 Novel compound
GB9821732 1998-10-06
GBGB9902935.7A GB9902935D0 (en) 1999-02-10 1999-02-10 Novel compound
GB9902935 1999-02-10

Publications (1)

Publication Number Publication Date
AU713877B3 true AU713877B3 (en) 1999-12-09

Family

ID=27269380

Family Applications (4)

Application Number Title Priority Date Filing Date
AU23938/99A Ceased AU713877B3 (en) 1998-07-02 1999-04-23 Novel compound
AU23937/99A Ceased AU713131B3 (en) 1998-07-02 1999-04-23 Novel compound
AU36191/99A Abandoned AU3619199A (en) 1998-07-02 1999-04-23 Paroxetine methanesulfonate
AU23928/99A Ceased AU732211C (en) 1998-07-02 1999-04-23 Novel compound

Family Applications After (3)

Application Number Title Priority Date Filing Date
AU23937/99A Ceased AU713131B3 (en) 1998-07-02 1999-04-23 Novel compound
AU36191/99A Abandoned AU3619199A (en) 1998-07-02 1999-04-23 Paroxetine methanesulfonate
AU23928/99A Ceased AU732211C (en) 1998-07-02 1999-04-23 Novel compound

Country Status (34)

Country Link
US (4) US6063927A (enExample)
EP (5) EP1020464B1 (enExample)
JP (1) JP2002519422A (enExample)
KR (1) KR20010053336A (enExample)
CN (1) CN1127502C (enExample)
AR (2) AR011759A1 (enExample)
AT (4) ATE195121T1 (enExample)
AU (4) AU713877B3 (enExample)
BE (3) BE1011664A6 (enExample)
BR (1) BR9911682A (enExample)
CA (1) CA2269999A1 (enExample)
CH (1) CH689805A8 (enExample)
DE (5) DE69900007T2 (enExample)
DK (7) DK199900176U3 (enExample)
ES (4) ES2158778B1 (enExample)
FI (2) FI4209U1 (enExample)
FR (2) FR2780728B1 (enExample)
GB (5) GB2339428A (enExample)
GR (3) GR990100140A (enExample)
HU (1) HUP0102334A3 (enExample)
IE (5) IE990344A1 (enExample)
IL (1) IL140628A (enExample)
IT (1) IT1312540B1 (enExample)
LU (1) LU90388B1 (enExample)
NL (4) NL1011875C2 (enExample)
NO (1) NO319030B1 (enExample)
NZ (1) NZ509180A (enExample)
PL (1) PL345214A1 (enExample)
PT (4) PT1089996E (enExample)
SE (1) SE9901462A0 (enExample)
SI (3) SI0970955T1 (enExample)
SK (1) SK20262000A3 (enExample)
TR (1) TR200100054T2 (enExample)
WO (1) WO2000001694A1 (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5998401A (en) * 1995-02-28 1999-12-07 Eli Lilly And Company Naphthyl compounds, intermediates, compositions, and methods
WO1998037938A1 (en) * 1997-02-27 1998-09-03 Ajinomoto Co., Inc. Crystallization apparatus and crystallization method
ATE200781T1 (de) * 1997-06-10 2001-05-15 Synthon Bv 4-phenylpiperidin-derivate
CH689805A8 (fr) * 1998-07-02 2000-02-29 Smithkline Beecham Plc Méthanesulfonate de paroxétine, procédé pour sa préparation et compositions pharmaceutiques le contenant.
US20040028582A1 (en) * 1999-03-10 2004-02-12 Smithkline Beecham Corporation Crystallization process for producing fine crystal products
USPP12225P2 (en) 1999-06-01 2001-11-27 Florfis Ag Geranium plant named ‘Fislamda’
ES2159260B1 (es) * 1999-06-22 2002-05-01 Smithkline Beechan Plc Nueva composicion de metanosulfonato de paroxetina
WO2000078290A2 (en) * 1999-06-22 2000-12-28 Smithkline Beecham P.L.C. Pharmaceutical composition comprising a salt of paroxetine
GB0003232D0 (en) * 2000-02-11 2000-04-05 Smithkline Beecham Plc Novel composition
US6306435B1 (en) 2000-06-26 2001-10-23 Yung Shin Pharmaceutical Industrial Co. Ltd. Oral pharmaceutical preparation embedded in an oily matrix and methods of making the same
GB0015981D0 (en) * 2000-06-29 2000-08-23 Glaxo Group Ltd Novel process for preparing crystalline particles
US6645523B2 (en) * 2000-08-28 2003-11-11 Synthon Bct Technologies, Llc Paroxetine compositions and processes for making the same
DE20100529U1 (de) * 2001-01-11 2001-05-10 Synthon Bv Pharmazeutische Tablette umfassend Paroxetinmesylat
NL1017421C2 (nl) * 2001-02-21 2002-01-15 Synthon Bv Werkwijze voor het vervaardigen van paroxetine.
EP1412350A1 (en) * 2001-08-02 2004-04-28 Spurcourt Limited Paroxetine isethionate salt, process of preparation and use in the treatment of depression
EP2316469A1 (en) 2002-02-22 2011-05-04 Shire LLC Delivery system and methods for protecting and administering dextroamphetamine
US20050266082A1 (en) * 2004-05-26 2005-12-01 Patel Satishkumar A Preparation of stable paroxetine HC1 ER tablets using a melt granulation process
WO2006018318A1 (en) * 2004-08-18 2006-02-23 Synthon B.V. Liquid paroxetine compositions
EP1791531A1 (en) * 2004-08-20 2007-06-06 Alpharma, Inc. Paroxetine formulations
KR100672184B1 (ko) 2004-09-21 2007-01-19 주식회사종근당 파록세틴의 콜린산 또는 콜린산 유도체 염
CA2603832C (en) * 2005-04-07 2011-11-22 Xy, Inc. Flow path conditioner system
US20070112031A1 (en) * 2005-11-14 2007-05-17 Gant Thomas G Substituted phenylpiperidines with serotoninergic activity and enhanced therapeutic properties
US8722884B2 (en) * 2005-12-01 2014-05-13 Verastem, Inc. Pyrimidine derivatives for the treatment of abnormal cell growth
US20080033050A1 (en) 2006-08-04 2008-02-07 Richards Patricia Allison Tewe Method of treating thermoregulatory disfunction with paroxetine
CA2679484A1 (en) * 2007-03-09 2008-09-18 Novartis Ag Salts of 3-(1h-ind0l-3-yl)-4-[2-(4-methyl-piperazin-i-yl)-quinazolin-4-yl]-pyrrole-2,5-dione
US20100249166A1 (en) * 2007-09-19 2010-09-30 Xy, Inc. Differential evaporation potentiated disinfectant system
US8119688B2 (en) * 2007-09-19 2012-02-21 Xy, Llc Differential evaporation potentiated disinfectant system
FR2926552B1 (fr) * 2008-01-23 2010-03-26 Biocodex Procede de preparation de particules de stiripentol ayant une granulometrie definie
CN103961333B (zh) * 2014-05-07 2020-02-21 浙江华海药业股份有限公司 甲磺酸帕罗西汀胶囊及其制备方法
CN104523645A (zh) * 2014-11-20 2015-04-22 美吉斯制药（厦门）有限公司 甲磺酸帕罗西汀片芯及其包衣片的制备方法
US11111373B2 (en) 2018-12-05 2021-09-07 Chi Mei Corporation Polymethacrylate composition and optical device made therefrom, and display apparatus

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3108097A (en) * 1997-06-10 1998-12-30 Synthon B.V. 4-phenylpiperidine compounds

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE99678C (enExample) *
GB1422263A (en) * 1973-01-30 1976-01-21 Ferrosan As 4-phenyl-piperidine compounds
US4585777A (en) * 1984-02-07 1986-04-29 A/S Ferrosan (-)-Trans-4-(4-fluorophenyl)-3-(4-methoxyphenoxy)methylpiperidine for potentiating 5-HT
GB8430581D0 (en) * 1984-12-04 1985-01-09 Ferrosan As Treatment
GB8431478D0 (en) * 1984-12-13 1985-01-23 Beecham Group Plc Compounds
EP0190496A3 (en) * 1984-12-13 1987-05-27 Beecham Group Plc Piperidine derivatives having a gastro-intestinal activity
GB8520154D0 (en) * 1985-08-10 1985-09-18 Beecham Group Plc Chemical process
EP0223334B1 (en) * 1985-08-10 1991-07-10 Beecham Group Plc Process for the preparation of aryl-piperidine carbinols
DE3677712D1 (de) * 1985-10-21 1991-04-04 Honda Motor Co Ltd Methode zur steuerung des spulenstroms eines magnetventils, das die saufluftmenge eines innenverbrennungsmotors steuert.
ES2058061T3 (es) * 1985-10-25 1994-11-01 Beecham Group Plc Derivado de piperidina, su preparacion y su uso como medicamento.
IE66332B1 (en) * 1986-11-03 1995-12-27 Novo Nordisk As Piperidine compounds and their preparation and use
GB8626936D0 (en) * 1986-11-11 1986-12-10 Ferrosan As Treatment
EP0269383A3 (en) * 1986-11-21 1990-05-02 A.H. Robins Company, Incorporated 1-Aryloxy-4-[(4-aryl)-1-piperazinyl]-2-butanols useful as antiallergy agents
GB8714707D0 (en) * 1987-06-23 1987-07-29 Beecham Group Plc Chemical process
DK715988D0 (da) * 1988-12-22 1988-12-22 Ferrosan As Etherifikation og dealkylering af piperidin-derivater samt intermediater
DK716088D0 (da) * 1988-12-22 1988-12-22 Ferrosan As Reduktion af piperidin-dion-derivater samt intermediat
KR930702000A (ko) * 1990-11-24 1993-09-08 데이빗 로버츠 노년기 치매, 식용항진, 편두통, 또는 식용불량의 치료를 위한 파로세틴의 사용
GB9209687D0 (en) * 1992-05-06 1992-06-17 Smithkline Beecham Plc Novel process
US5258517A (en) * 1992-08-06 1993-11-02 Sepracor, Inc. Method of preparing optically pure precursors of paroxetine
JP2773587B2 (ja) * 1992-11-30 1998-07-09 東レ株式会社 Ｏ，ｏ´−ジアシル酒石酸無水物の製造法
US5276042A (en) * 1993-04-16 1994-01-04 Crenshaw Roger T Treatment of premature ejaculation
US5546683A (en) * 1993-09-29 1996-08-20 Clark; George J. Bucket attachment device with remote controlled retractable pins
IT1274241B (it) * 1993-12-03 1997-07-15 Smithkline Beecham Farma Complessi agente terapeutico/matrice polimerica dotati di migliorate caratteristiche di sapore e composizioni farmaceutiche che li contengono
GB9325644D0 (en) * 1993-12-15 1994-02-16 Smithkline Beecham Plc Novel formulation
US5668134A (en) * 1994-01-28 1997-09-16 G. D. Searle & Co. Method for preventing or reducing photosensitivity and/or phototoxicity reactions to medications
GB9402029D0 (en) * 1994-02-03 1994-03-30 Smithkline Beecham Plc Novel formulation
CA2143070C (en) * 1994-02-22 2001-12-18 Pankaj Modi Oral controlled release liquid suspension pharmaceutical formulation
EP0714663A3 (en) * 1994-11-28 1997-01-15 Lilly Co Eli Potentiation of drug responses by serotonin 1A receptor antagonists
SK283608B6 (sk) * 1995-02-06 2003-10-07 Smithkline Beecham Plc Bezvodý hydrochlorid paroxetínu, spôsob jeho výroby a použitie
GB2297550C2 (en) * 1995-02-06 1997-04-09 Smithkline Beecham Plc Paroxetine hydrochloride anhydrate substantially free of bound organic solvent
EP0818990A1 (en) * 1995-04-03 1998-01-21 Abbott Laboratories Homogeneous mixtures of low temperature-melting drugs and additives for controlled release
WO1996036636A1 (en) * 1995-05-17 1996-11-21 Novo Nordisk A/S Process for preparing 4-aryl-piperidine derivatives
JP2813768B2 (ja) * 1995-05-24 1998-10-22 農林水産省家畜衛生試験場長 口蹄疫診断用ペプチドおよび当該ペプチドを含有する口蹄疫診断用抗原
GB9514842D0 (en) * 1995-07-20 1995-09-20 Smithkline Beecham Plc Novel formulation
JP3081250B2 (ja) * 1995-10-31 2000-08-28 メルク エンド カンパニー インコーポレーテッド 置換アゼチジノンの製造方法
IT1276160B1 (it) * 1995-11-22 1997-10-27 Recordati Chem Pharm Composizioni farmaceutiche orali a pronto rilascio per sospensioni estemporanee
GB9526645D0 (en) * 1995-12-28 1996-02-28 Chiroscience Ltd Stereoselective synthesis
ES2117557B1 (es) * 1996-02-29 1999-07-01 Ferrer Int Nuevo procedimiento de obtencion de (-)-trans -n-p-fluorobenzoilmetil-4-(p-fluorofenil)-3- ((3,4-(metilendioxi)fenoxi ) metil)-piperidina.
JP3446468B2 (ja) * 1996-04-15 2003-09-16 旭硝子株式会社 ピペリジンカルビノール類の製造方法
CA2206592A1 (en) * 1996-05-30 1997-11-30 Shu-Zhong Wang Method of producing amorphous paroxetine hydrochloride
JP3882224B2 (ja) * 1996-05-31 2007-02-14 旭硝子株式会社 パロキセチンの製造方法
DE69739561D1 (de) * 1996-06-13 2009-10-15 Sumitomo Chemical Co Piperidin Derivative als Zwischenprodukte zur Herstellung von Paroxetine und Verfahren zu ihrer Herstellung
HU221921B1 (hu) * 1996-07-08 2003-02-28 Richter Gedeon Vegyészeti Gyár Rt. N-benzil-piperidin- és tetrahidropiridinszármazékok és eljárás azok előállítására
US5672609A (en) * 1996-07-18 1997-09-30 Eli Lilly And Company Pyridine compounds, intermediates compositions and methods of use
CA2187128A1 (en) * 1996-10-04 1997-06-26 K. S. Keshava Murthy New and useful polymorph of anhydrous paroxetine hydrochloride
CA2319652A1 (en) * 1998-02-06 1999-08-12 Michael Urquhart Salts of paroxetine
ID27596A (id) * 1998-03-16 2001-04-12 Smithkline Beecham Plc Bentuk paroksetina kristal
HUP0103651A3 (en) * 1998-04-09 2002-12-28 Smithkline Beecham Plc Paroxetine maleate and process for its preparation
CH689805A8 (fr) * 1998-07-02 2000-02-29 Smithkline Beecham Plc Méthanesulfonate de paroxétine, procédé pour sa préparation et compositions pharmaceutiques le contenant.
ES2159260B1 (es) * 1999-06-22 2002-05-01 Smithkline Beechan Plc Nueva composicion de metanosulfonato de paroxetina
DE20100529U1 (de) * 2001-01-11 2001-05-10 Synthon Bv Pharmazeutische Tablette umfassend Paroxetinmesylat

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3108097A (en) * 1997-06-10 1998-12-30 Synthon B.V. 4-phenylpiperidine compounds

Also Published As

Publication number Publication date
ES2209428T3 (es) 2004-06-16
PL345214A1 (en) 2001-12-03
NL1011875A1 (nl) 2000-01-07
NL1011875C2 (nl) 2000-03-24
IL140628A (en) 2004-06-20
EP0970955A1 (en) 2000-01-12
FR2780728B1 (fr) 2001-02-16
ES2158778B1 (es) 2002-03-16
BE1011664A6 (fr) 1999-11-09
AU732211B2 (en) 2001-04-12
EP1020463A1 (en) 2000-07-19
EP1020464A1 (en) 2000-07-19
GB2377637A (en) 2003-01-22
ITMI990866A1 (it) 2000-10-23
NO319030B1 (no) 2005-06-06
DK199900176U3 (da) 1999-08-13
EP1089996B1 (en) 2003-10-01
AU713131B3 (en) 1999-11-25
DK199900554A (da) 2000-01-03
PT970955E (pt) 2000-11-30
GR990100140A (el) 2000-03-31
AU3619199A (en) 2000-01-24
DK200000390U1 (da) 2000-12-27
ATE195121T1 (de) 2000-08-15
EP1089996A1 (en) 2001-04-11
DK1020464T3 (da) 2001-09-24
DE19918588A1 (de) 2000-01-27
LU90388B1 (fr) 2001-01-29
IE20000633A1 (en) 2001-10-17
FIU990190U0 (fi) 1999-04-23
WO2000001694A1 (en) 2000-01-13
AU2392899A (en) 2000-01-20
GB0119695D0 (en) 2001-10-03
GB0216752D0 (en) 2002-08-28
GR1003350B (el) 2000-03-29
DK199900234U1 (da) 2000-12-22
DE29907248U1 (de) 1999-09-09
AU732211C (en) 2004-05-06
SE9901462A0 (sv) 2000-01-03
SE9901462D0 (sv) 1999-04-23
NO991944D0 (no) 1999-04-23
DE69911774T2 (de) 2004-08-05
FI4209U1 (fi) 1999-11-10
JP2002519422A (ja) 2002-07-02
US20020035130A1 (en) 2002-03-21
SI1020464T1 (en) 2001-12-31
AR018197A1 (es) 2001-10-31
NO991944L (no) 2000-01-03
GB2339428A (en) 2000-01-26
TR200100054T2 (tr) 2001-06-21
GB2336364B (en) 2000-05-10
US20020193406A1 (en) 2002-12-19
DK0970955T3 (da) 2000-10-09
CN1127502C (zh) 2003-11-12
AT3185U2 (de) 1999-11-25
GB2352395B (en) 2004-02-11
IT1312540B1 (it) 2002-04-22
GB0026487D0 (en) 2000-12-13
IL140628A0 (en) 2002-02-10
CH689805A5 (fr) 1999-11-30
DK1089996T3 (da) 2004-02-09
BE1012403A5 (fr) 2000-10-03
SI1089996T1 (en) 2004-04-30
NL1011874C1 (nl) 1999-07-12
ES2157881T3 (es) 2001-09-01
DE60000003D1 (de) 2001-08-09
IES20000893A2 (en) 2001-05-30
NL1012272C1 (nl) 1999-07-12
FR2802098A1 (fr) 2001-06-15
PT102291B (pt) 2002-07-31
SI0970955T1 (en) 2001-02-28
AR011759A1 (es) 2000-09-13
EP0970955B1 (en) 2000-08-02
NL1012271C2 (nl) 1999-09-23
IE990344A1 (en) 2000-05-03
ATE251155T1 (de) 2003-10-15
FI990922L (fi) 2000-01-03
EP1020464B1 (en) 2001-07-04
IES20000894A2 (en) 2001-05-30
FI112077B (fi) 2003-10-31
ES2158778A1 (es) 2001-09-01
CH689805A8 (fr) 2000-02-29
GB2352395A (en) 2001-01-31
ATE202777T1 (de) 2001-07-15
FI990922A0 (fi) 1999-04-23
ES2149044T3 (es) 2000-10-16
NL1012271A1 (nl) 1999-07-12
PT1089996E (pt) 2004-02-27
SK20262000A3 (sk) 2001-07-10
US6063927A (en) 2000-05-16
DE69900007D1 (de) 2000-09-07
GR3034328T3 (en) 2000-12-29
FR2780728A1 (fr) 2000-01-07
DE69900007T2 (de) 2001-06-07
DE60000003T2 (de) 2002-03-21
DK199900234U4 (da) 2000-12-22
PT102291A (pt) 2000-05-31
HUP0102334A2 (hu) 2002-05-29
CA2269999A1 (en) 2000-01-02
CN1315949A (zh) 2001-10-03
HK1037877A1 (en) 2002-02-22
US20010023253A1 (en) 2001-09-20
EP1288214A1 (en) 2003-03-05
NZ509180A (en) 2001-06-29
IES81166B2 (en) 2000-05-31
AT3185U3 (de) 2000-01-25
GB2336364A (en) 1999-10-20
GB9920332D0 (en) 1999-11-03
HUP0102334A3 (en) 2003-12-29
GR3036208T3 (en) 2001-10-31
KR20010053336A (ko) 2001-06-25
SE9901462L (enExample)
GB2367003A (en) 2002-03-27
DE69911774D1 (de) 2003-11-06
GB9909505D0 (en) 1999-06-23
PT1020464E (pt) 2001-10-30
IES990343A2 (en) 2000-01-02
BE1012420A6 (fr) 2000-10-03
BR9911682A (pt) 2001-12-26

Similar Documents

Publication Publication Date Title
AU713877B3 (en) Novel compound
AU2002100370A4 (en) Novel compound
US20040247667A1 (en) Novel compound
AU724845B3 (en) Novel compound
AU2001100025A4 (en) Novel compound
AU732558B3 (en) Novel compound
AU5430701A (en) Novel compound
HK1030603A (en) Paroxetine methanesulfonate
HK1030773A (en) Paroxetine methanesulfonate
IES83541Y1 (en) Paroxetine methanesulfonate
CZ20004924A3 (cs) Methansulfonat paroxetinu
MXPA01000307A (en) Paroxetine methanesulfonate

Legal Events

Date Code Title Description
NCF Extension of term for petty patent requested (sect. 69)
MAY Offer to surrender petty patent
MK14 Patent ceased section 143(a) (annual fees not paid) or expired
TH Corrigenda

Free format text: IN VOL 15, NO 23, PAGE(S) 5026 UNDER THE HEADING OFFER TO SURRENDER PETTY PATENT PLEASE DELETE ALL REFERENCE TO PETTY PATENT NO. 713877